Charcoal, Activated

Summary

Charcoal, Activated (CHEMBL2106049) is a phase-3 clinical-stage small molecule (ATC A07BA01); indicated across 15 conditions including inflammatory bowel disease and chronic kidney disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A07BA01 (+1 more)
• Indications: 15 conditions
• Clinical trials: 58
• Chemistry: 16.043 Da · CH4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106049
Name	Charcoal, Activated
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	297
ChEBI	CHEBI:27594
ATC	A07BA01, A07BA51
Molecular formula	CH4
Molecular weight	16.043
InChIKey	VNWKTOKETHGBQD-UHFFFAOYSA-N

SMILES: C

IUPAC name: methane

Pharmacological roles (ChEBI): macronutrient.

Also known as: Activated charcoal, Ast 120, AST-120, Carbo vegetabilis, Carbon, medicinal, Charcoal, activated, Medicinal carbon, Medicinal charcoal, CHARCOAL, ACTIVATED

Patent coverage: 4,335,983 distinct patent families (8,686,700 SureChEMBL compound mentions), from 61 matched compound structure(s). One matched structure accounts for 8,685,780 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

15 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
inflammatory bowel disease	3	MONDO:0005265	EFO:0003767
chronic kidney disease	3	MONDO:0005300	EFO:0003884
gastric neoplasm	3	MONDO:0021085	MONDO:0001056
multiple sclerosis	3	MONDO:0005301	MONDO:0005301
irritable bowel syndrome	2	MONDO:0005052	EFO:0000555
pouchitis	2	MONDO:0005312	EFO:0003921
gastroesophageal reflux disease	2	MONDO:0007186	EFO:0003948
brain disorder	2	MONDO:0005560	HP:0001298
lung neoplasm	2	MONDO:0021117	MONDO:0008903
chronic obstructive pulmonary disease	1	MONDO:0005002	EFO:0000341
insomnia	1	MONDO:0013600	EFO:0004698
major depressive disorder	1	MONDO:0002009	MONDO:0002009
asthma	1	MONDO:0004979	MONDO:0004979
type 2 diabetes mellitus	1	MONDO:0005148	MONDO:0005148
allergic disease	1	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 58.

Phase distribution

Phase	Trials
PHASE1	18
PHASE2	12
Not specified	11
PHASE4	7
PHASE3	7
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05471479	PHASE4	RECRUITING	Activated CHARcoal in Poisoned Patient - Pilot Trial
NCT07182422	PHASE4	RECRUITING	AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease
NCT00860431	PHASE4	COMPLETED	Kremezin Study Against Renal Disease Progression in Korea
NCT01681303	PHASE4	COMPLETED	Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients.
NCT02969746	PHASE4	WITHDRAWN	Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
NCT04639674	PHASE4	COMPLETED	AST-120 in Hemodialysis Patients With Uremic Pruritus
NCT06219967	PHASE4	COMPLETED	Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy
NCT06141473	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT00321412	PHASE3	COMPLETED	Safety and Efficacy of AST-120 in Mild to Moderate Crohn’s Patients With Fistulas
NCT00500682	PHASE3	COMPLETED	A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
NCT00501046	PHASE3	COMPLETED	A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
NCT00678366	PHASE3	COMPLETED	Evaluation of Adding Small Amounts of Oxygen to the CO2 Pneumoperitoneum Upon Pain and Inflammation
NCT01863888	PHASE3	COMPLETED	Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
NCT02123407	PHASE3	UNKNOWN	Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer
NCT05540431	PHASE2/PHASE3	UNKNOWN	Evaluation of Protective Effect of Activated Charcoal and Probiotic Against Progression of Chronic Kidney Disease
NCT06579066	PHASE2	NOT_YET_RECRUITING	The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus.
NCT06906874	PHASE2	RECRUITING	Activated Charcoal Use in Chronic Kidney Disease Patients
NCT00558038	PHASE2	COMPLETED	Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
NCT00583076	PHASE2	COMPLETED	Safety and Efficacy of AST-120 in the Treatment of Pouchitis
NCT00583128	PHASE2	COMPLETED	Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome
NCT00583531	PHASE2	TERMINATED	Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
NCT00587275	PHASE2	TERMINATED	Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
NCT00867698	PHASE2	COMPLETED	AST-120 Used to Treat Mild Hepatic Encephalopathy
NCT01811394	PHASE2	UNKNOWN	Ion Irradiation of Sacrococcygeal Chordoma
NCT04311645	PHASE2	UNKNOWN	Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous
NCT04928950	PHASE2	WITHDRAWN	Charcoal in Lung Cancer Patients Undergoing TEMLA
NCT05229874	PHASE2	UNKNOWN	Effect of CNSI vs. ICG in Lymph Node Tracing During Gastrectomy
NCT00719758	PHASE1	COMPLETED	Drug-Drug Interaction Study of TRK-100STP
NCT01236105	PHASE1	COMPLETED	Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject
NCT01257191	PHASE1	COMPLETED	A Study to Compare the Effects of Different Sized Particles on Cells in the Nose
NCT01280175	PHASE1	COMPLETED	Foster With or Without Charcoal Block or Aerochamber Plus
NCT01389752	PHASE1	COMPLETED	A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
NCT01409369	PHASE1	COMPLETED	A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819
NCT01593826	PHASE1	COMPLETED	Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler
NCT01627158	PHASE1	COMPLETED	Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte
NCT01766843	PHASE1	COMPLETED	Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus
NCT01856621	PHASE1	COMPLETED	Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus
NCT02657512	PHASE1	COMPLETED	Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
NCT02691325	PHASE1	COMPLETED	Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
NCT03073057	PHASE1	COMPLETED	Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).